Skip to content
Kevzara(sarilumab)
Kevzara (sarilumab) is an antibody pharmaceutical. Sarilumab was first approved as Kevzara on 2017-05-22. It is used to treat rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against interleukin-6 receptor subunit alpha.
Download report
Favorite
COVID-19
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Kevzara
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Sarilumab
Tradename
Proper name
Company
Number
Date
Products
KevzarasarilumabSanofiN-761037 RX2017-05-22
4 products
Labels
FDA
EMA
Brand Name
Status
Last Update
kevzaraBiologic Licensing Application2019-09-17
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
rheumatoid arthritisEFO_0000685D001172M06.9
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AC: Interleukin inhibitors
— L04AC14: Sarilumab
HCPCS
No data
Clinical
Clinical Trials
53 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Rheumatoid arthritisD001172EFO_0000685M06.993132126
AtherosclerosisD050197EFO_0003914I25.1———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382U07.1152—17
PneumoniaD011014EFO_0003106J18——1——1
Polymyalgia rheumaticaD011111EFO_0008518M35.3——1——1
Giant cell arteritisD013700EFO_1001209M31.6——1——1
Allergic contact dermatitisD017449L23—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Juvenile arthritisD001171EFO_0002609M08—2———2
Ankylosing spondylitisD013167EFO_0003898M45—2———2
NeoplasmsD009369C8011———1
Castration-resistant prostatic neoplasmsD06412911———1
UveitisD014605EFO_1001231H20.9—1———1
Sars-cov-2D000086402—1———1
Borna disease virusD001891—1———1
SarcoidosisD012507EFO_0000690D80-D89—1———1
Systemic mastocytosisD034721C96.21—1———1
Localized sclerodermaD012594L94.011———1
Show 1 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung neoplasmsD008175C34.901————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSARILUMAB
INNsarilumab
Description
Sarilumab (human mab)
Classification
Antibody
Drug classantiviral (arildone derivatives); monoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID1189541-98-7
RxCUI1923319
ChEMBL IDCHEMBL2108730
ChEBI ID—
PubChem CID—
DrugBankDB11767
UNII IDNU90V55F8I (ChemIDplus, GSRS)
Target
Agency Approved
IL6R
IL6R
Organism
Homo sapiens
Gene name
IL6R
Gene synonyms
NCBI Gene ID
3570
Protein name
interleukin-6 receptor subunit alpha
Protein synonyms
CD126, CD126 antigen, gp80, IL-6 receptor subunit alpha, IL-6R 1, Membrane glycoprotein 80
Uniprot ID
Q5VZ23
Mouse ortholog
Il6ra (16194)
interleukin-6 receptor subunit alpha (P22272)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Kevzara - Regeneron Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3,724 documents
View more details
Safety
Black-box Warning
Black-box warning for: Kevzara
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,393 adverse events reported
View more details